Bright Minds Biosciences Appoints Stephen Collins As CMO

(RTTNews) - Bright Minds Biosciences, Inc. (DRUG), a company focused on drug-resistant epilepsy, depression, and other central nervous system disorders, said on Tuesday that it has appointed Stephen D. Collins as Chief Medical Officer with immediate effect.

The company has also announced that Mark A. Smith will retire from his role as Acting CMO but will continue to serve in an advisory capacity.

Prior to joining Bright Minds, Collins simultaneously served as CEO of Biscayne Neurotherapeutics and CEO of Biscayne Pharmaceuticals, which was sold to Supernus Pharmaceuticals in 2018.